Discussing pathologic mechanisms of Diabetic retinopathy & therapeutic potentials of curcumin and β-glucogallin in the management of Diabetic retinopathy
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
Diabetic retinopathy (DR) is a form of retinal microangiopathy that occurs as a result of long-term Diabetes mellitus (DM). Patients with Diabetes mellitus typically suffer from DR as a progression of the disease that may be due to initiation and dysregulation of pathways like the polyol, hexosamine, the AGE/RAGE, and the PKC pathway, which all have negative impacts on eye health and vision. In this review, various databases, including PubMed, Google Scholar, Web of Science, and Science Direct, were scoured for data relevant to the aforementioned title. The three most common therapies for DR today are retinal photocoagulation, anti-vascular endothelial growth factor (VEGF) therapy, and vitrectomy, however, there are a number of drawbacks and limits to these methods. So, it is of critical importance and profound interest to discover treatments that may successfully address the pathogenesis of DR. Curcumin and β-glucogallin are the two potent compounds of natural origin that are already being used in various nutraceutical formulations for several ailments. They have been shown potent antiapoptotic, anti-inflammatory, antioxidant, anticancer, and pro-vascular function benefits in animal experiments. Their parent plant species have been used for generations by practitioners of traditional herbal medicine for the treatment and prevention of various eye ailments. In this review, we will discuss about pathophysiology of Diabetic retinopathy and the therapeutic potentials of curcumin and β-glucogallin one of the principal compounds from Curcuma longa and Emblica officinalis in Diabetic retinopathy.
| Errataetall: |
ErratumIn: Biomed Pharmacother. 2023 Dec 9;:115980. - PMID 38072750 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:169 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 169(2023) vom: 31. Dez., Seite 115881 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rohilla, Manni [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
β-Glucogallin |
|---|
| Anmerkungen: |
Date Completed 07.12.2023 Date Revised 10.12.2023 published: Print-Electronic ErratumIn: Biomed Pharmacother. 2023 Dec 9;:115980. - PMID 38072750 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2023.115881 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364803150 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364803150 | ||
| 003 | DE-627 | ||
| 005 | 20231227132034.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2023.115881 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1226.xml |
| 035 | |a (DE-627)NLM364803150 | ||
| 035 | |a (NLM)37989030 | ||
| 035 | |a (PII)S0753-3322(23)01679-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rohilla, Manni |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Discussing pathologic mechanisms of Diabetic retinopathy & therapeutic potentials of curcumin and β-glucogallin in the management of Diabetic retinopathy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.12.2023 | ||
| 500 | |a Date Revised 10.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Biomed Pharmacother. 2023 Dec 9;:115980. - PMID 38072750 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a Diabetic retinopathy (DR) is a form of retinal microangiopathy that occurs as a result of long-term Diabetes mellitus (DM). Patients with Diabetes mellitus typically suffer from DR as a progression of the disease that may be due to initiation and dysregulation of pathways like the polyol, hexosamine, the AGE/RAGE, and the PKC pathway, which all have negative impacts on eye health and vision. In this review, various databases, including PubMed, Google Scholar, Web of Science, and Science Direct, were scoured for data relevant to the aforementioned title. The three most common therapies for DR today are retinal photocoagulation, anti-vascular endothelial growth factor (VEGF) therapy, and vitrectomy, however, there are a number of drawbacks and limits to these methods. So, it is of critical importance and profound interest to discover treatments that may successfully address the pathogenesis of DR. Curcumin and β-glucogallin are the two potent compounds of natural origin that are already being used in various nutraceutical formulations for several ailments. They have been shown potent antiapoptotic, anti-inflammatory, antioxidant, anticancer, and pro-vascular function benefits in animal experiments. Their parent plant species have been used for generations by practitioners of traditional herbal medicine for the treatment and prevention of various eye ailments. In this review, we will discuss about pathophysiology of Diabetic retinopathy and the therapeutic potentials of curcumin and β-glucogallin one of the principal compounds from Curcuma longa and Emblica officinalis in Diabetic retinopathy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Curcumin | |
| 650 | 4 | |a Diabetes | |
| 650 | 4 | |a Diabetic retinopathy | |
| 650 | 4 | |a Pathologic mechanism | |
| 650 | 4 | |a β-Glucogallin | |
| 650 | 7 | |a Curcumin |2 NLM | |
| 650 | 7 | |a IT942ZTH98 |2 NLM | |
| 650 | 7 | |a glucogallin |2 NLM | |
| 650 | 7 | |a 58511-73-2 |2 NLM | |
| 650 | 7 | |a Hydrolyzable Tannins |2 NLM | |
| 700 | 1 | |a Rishabh |e verfasserin |4 aut | |
| 700 | 1 | |a Bansal, Seema |e verfasserin |4 aut | |
| 700 | 1 | |a Garg, Anjali |e verfasserin |4 aut | |
| 700 | 1 | |a Dhiman, Sachin |e verfasserin |4 aut | |
| 700 | 1 | |a Dhankhar, Sanchit |e verfasserin |4 aut | |
| 700 | 1 | |a Saini, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Chauhan, Samrat |e verfasserin |4 aut | |
| 700 | 1 | |a Alsubaie, Nawal |e verfasserin |4 aut | |
| 700 | 1 | |a Batiha, Gaber El-Saber |e verfasserin |4 aut | |
| 700 | 1 | |a Albezrah, Nisreen Khalid Aref |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Thakur Gurjeet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 169(2023) vom: 31. Dez., Seite 115881 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:169 |g year:2023 |g day:31 |g month:12 |g pages:115881 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2023.115881 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 169 |j 2023 |b 31 |c 12 |h 115881 | ||